Thermo Fisher Scientific (TMO) Q3 FY26 earnings call

Thermo Fisher Scientific delivered an outstanding third quarter, marked by strong financial performance and continued improvement in end market conditions. The company raised its full-year guidance for both revenue and adjusted EPS, driven by robust operational execution and strategic investments in innovation and AI. Management highlighted the strengthening biotech market and the positive impact of AI on drug development, positioning the company for sustained long-term growth.